Top Page
MedPlus Health Services Ltd.
(MEDPLUS)
MedPlus Health Services Ltd. (MEDPLUS) vs. iShares MSCI India ETF (INDA)
MedPlus Health Services Ltd. Business Overview & Revenue Model
MedPlus Health Services Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 61.90B | 61.36B | 56.25B | 45.58B | 37.79B | 30.69B |
| Gross Profit | 15.44B | 14.70B | 12.14B | 9.82B | 7.85B | 6.38B |
| EBITDA | 3.56B | 3.24B | 2.08B | 1.41B | 1.87B | 1.52B |
| Net Income | 1.78B | 1.50B | 654.73M | 497.63M | 958.02M | 638.58M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 33.60B | 30.05B | 27.97B | 25.94B | 15.66B |
| Cash, Cash Equivalents and Short-Term Investments | 3.67B | 4.40B | 1.65B | 2.89B | 6.58B | 1.49B |
| Total Debt | 0.00 | 11.20B | 10.10B | 9.05B | 8.15B | 5.90B |
| Total Liabilities | -17.40B | 16.20B | 14.27B | 13.06B | 11.77B | 8.35B |
| Stockholders Equity | 17.40B | 17.41B | 15.78B | 14.91B | 14.18B | 7.31B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 4.95B | 593.38M | -785.95M | 521.68M | -513.67M |
| Operating Cash Flow | 0.00 | 5.54B | 1.44B | 904.10M | 1.70B | 28.91M |
| Investing Cash Flow | 0.00 | -3.32B | -827.99M | 4.29B | -7.03B | -345.49M |
| Financing Cash Flow | 0.00 | -2.28B | -1.98B | -1.70B | 4.40B | -56.26M |
MedPlus Health Services Ltd. Technical Analysis
MedPlus Health Services Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ₹101.85B | 67.23 | ― | 0.20% | 16.71% | 13.92% | |
67 Neutral | ₹90.12B | 252.67 | ― | ― | 17.58% | -38.20% | |
66 Neutral | ₹237.42B | 44.23 | ― | 0.89% | 10.80% | 32.79% | |
62 Neutral | ₹98.09B | 50.21 | ― | ― | 4.94% | 94.22% | |
61 Neutral | ₹99.74B | 62.88 | ― | 0.21% | 15.41% | 5.93% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
40 Neutral | ₹20.18B | -18.25 | ― | 0.08% | -2.81% | -444.69% |
MedPlus Health Services Ltd. Corporate Events
MedPlus Health Services Ltd. has disclosed that its subsidiary, Optival Health Solutions Private Limited, has received a two-day suspension of the drug license for one of its retail pharmacy stores located on S Rammurthy Road in Virajpet, Karnataka, following an order from the Assistant Director, Drugs Control Administration, Madikeri Circle, under Rule 65 of the Drugs and Cosmetics Act, 1940 and associated Rules. The company estimates a potential revenue loss of approximately Rs 0.74 lakh from this temporary suspension, indicating that the operational and financial impact is limited and localized to a single outlet, with no broader disruption to MedPlus’s overall retail network or core business activities communicated at this time.
MedPlus Health Services Limited has disclosed that its subsidiary, Optival Health Solutions Private Limited, has received a one-day suspension order of the drug license for a retail store located on KC Rani Road in Gadag, Karnataka, issued by the Assistant Director of the state Drugs Control Administration. The suspension, imposed under Rule 65 of the Drugs and Cosmetics Act, 1940 and corresponding rules, is expected to result in an estimated potential revenue loss of about Rs 0.23 lakh, suggesting only a minimal financial and operational impact on the company’s overall business and stakeholders.
Agilemed Investments Private Limited, a promoter entity of MedPlus Health Services Limited, has released a pledge on 4,171,970 equity shares of the company. The disclosure, made under Regulation 31 of SEBI’s Substantial Acquisition of Shares and Takeovers Regulations, 2011, signals a reduction in encumbrances on promoter-held shares, which may be viewed positively by investors as it can indicate improved financial flexibility and a stronger governance position for the listed pharmacy chain.
MedPlus Health Services Limited has disclosed that its subsidiary, Optival Health Solutions Private Limited, has received two suspension orders affecting drug licenses for retail pharmacy stores in Telangana and Maharashtra. The Jawahar Nagar store in Telangana faces a three-day license suspension ordered by the Assistant Director of the Drugs Control Administration, while the Radha Nagar-Kalyan store in Maharashtra faces a seven-day suspension ordered by the Food and Drug Administration, Mumbai; together, the suspensions are expected to result in a potential revenue loss of about Rs 5.54 lakh but are not indicated to materially disrupt the company’s overall operations.
MedPlus Health Services Ltd. has disclosed that its subsidiary Optival Health Solutions Private Limited has received three suspension orders for drug licenses covering three stores in Karnataka, located at Jayanagar 9th Block, T R Nagar, and Shiggon Haveri. The suspensions, issued by Assistant Directors of the Drugs Control Administration in Bangalore Circle-3 and Haveri Circle under Rule 65 of the Drugs and Cosmetics Act, 1940 and corresponding Rules, each apply for a three-day period and are linked to alleged violations of those provisions. The company estimates a combined potential revenue loss of roughly Rs 3.24 lakh from the temporary shutdowns, indicating a limited financial impact relative to overall operations, but highlighting ongoing regulatory scrutiny over compliance in its retail pharmacy network.
MedPlus Health Services Limited has disclosed that its promoter entity, Agilemed Investments Private Limited, has created a pledge over 48,51,066 equity shares of the company in compliance with Regulation 31 of SEBI’s Substantial Acquisition of Shares and Takeovers Regulations, 2011. The move, formally notified to BSE and NSE, represents an encumbrance on a portion of the promoter’s holdings and is significant for investors tracking promoter share pledging activity, as it may influence perceptions of the company’s capital structure and promoter financing position, though no change in control or ownership has been indicated.
MedPlus Health Services Ltd. announced that its subsidiary, Optival Health Solutions Private Limited, has received three suspension orders for the Drug License of a store in Maharashtra. The suspensions, issued by the Food & Drug Administration in Amravati and Nagpur, are expected to result in a potential revenue loss of approximately Rs 10.17 lacs. This development may impact the company’s financial operations and highlights regulatory challenges in maintaining compliance with the Drugs and Cosmetics Act.
MedPlus Health Services Ltd. announced that its subsidiary, Optival Health Solutions Private Limited, has received a two-day suspension order for a drug license at a store in Telangana. This suspension, issued by the Drugs Control Administration, is expected to result in a potential revenue loss of approximately Rs 0.87 lacs, highlighting a minor operational setback for the company.
MedPlus Health Services Ltd. announced that its subsidiary, Optival Health Solutions Private Limited, has received a two-day suspension order for a drug license at one of its stores in Telangana. This suspension, issued by the Assistant Director of Drugs Control Administration, is due to violations under the Drugs and Cosmetics Act, 1940, and is expected to result in a potential revenue loss of approximately Rs 1.43 lacs, impacting the company’s financial operations.
MedPlus Health Services Ltd. announced that its subsidiary, Optival Health Solutions Private Limited, has received a one-day suspension order for a drug license at a store located in Alnavara, Karnataka. This suspension, issued under the Drugs and Cosmetics Act, 1940, and related rules, is expected to result in a potential revenue loss of approximately Rs 0.33 Lacs, impacting the company’s financial operations.
MedPlus Health Services Ltd. announced that its subsidiary, Optival Health Solutions Private Limited, has received suspension orders for drug licenses at three of its stores located in Karnataka and Telangana. The suspensions, issued by the Drugs Control Administration, are expected to result in a potential revenue loss of approximately Rs 2.88 lacs. This development may impact the company’s short-term financial operations, but the overall implications for its market positioning remain to be seen.
MedPlus Health Services Ltd. announced that its subsidiary, Optival Health Solutions Private Limited, received a suspension order for a Drug License at a store in Telangana. The suspension, issued under the Drugs and Cosmetics Act, 1940, will last for three days and is expected to result in a potential revenue loss of approximately Rs 1.73 lacs. This incident highlights regulatory compliance challenges that could impact the company’s operations and financial performance.
MedPlus Health Services Ltd. has announced that its subsidiary, Optival Health Solutions Private Limited, received a suspension order for a Drug License at a store in Maharashtra. This suspension, issued by the Food & Drug Administration in Nagpur, is due to alleged violations under the Drugs and Cosmetics Act, 1940, and is expected to result in a potential revenue loss of approximately Rs 4.34 lacs. The suspension highlights regulatory challenges and could impact the company’s financial operations and market positioning in the region.
MedPlus Health Services Ltd. announced the approval of its unaudited standalone and consolidated financial results for the quarter and half-year ending September 30, 2025, by its Board of Directors. The results, reviewed by the company’s statutory auditors, indicate compliance with the SEBI regulations and reflect the company’s financial health and operational performance. The financial results are accessible on the company’s website and major stock exchanges, which underscores MedPlus’s commitment to transparency and regulatory adherence.
MedPlus Health Services Ltd. announced that its subsidiary, Optival Health Solutions Private Limited, has received suspension orders for drug licenses at two of its stores in Karnataka and Telangana. These suspensions, issued by the Drugs Control Administration, are expected to result in a potential revenue loss of approximately Rs 1.51 lacs. This development may impact the company’s short-term financial operations but is unlikely to have a significant long-term effect on its market position.
MedPlus Health Services Ltd. announced that its subsidiary, Optival Health Solutions Private Limited, has received suspension orders for drug licenses at two store locations in Karnataka. The suspensions, issued by the Drugs Control Administration, are expected to result in a potential revenue loss of approximately Rs 2.83 lacs. This development may impact the company’s financial operations and highlights regulatory challenges in maintaining compliance with drug and cosmetic regulations.
MedPlus Health Services Ltd. announced that its subsidiary, Optival Health Solutions Private Limited, has received two suspension orders for a Drug License at its Telangana stores. The suspensions, issued by the Drugs Control Administration, Medchal, are due to violations under the Drugs and Cosmetics Act, 1940 and Rules, 1945. The suspensions are expected to result in a potential revenue loss of approximately Rs 0.48 lacs and Rs 1.28 lacs for the affected stores. This development may impact the company’s financial operations and highlights regulatory compliance challenges within the industry.